-+ 0.00%
-+ 0.00%
-+ 0.00%

Actuate Therapeutics Announces Publication of Positive Phase II Clinical Data for Elraglusib Combined with Platinum Chemotherapy and Sequential Immunotherapy in Recurrent, Metastatic Salivary Gland Carcinoma

Barchart·12/15/2025 07:45:00
語音播報

Promising data show a median overall survival of 18.6 months, with 40% of patients alive at 2 years.

Results suggest that nuclear GSK-3β expression may help identify patients
most likely to respond to treatment of a historically difficult-to-treat refractory disease

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.